{"id":"https://openalex.org/W4200521908","doi":"https://doi.org/10.1093/ofid/ofab466.1651","title":"LB15. SER-109, an Investigational Microbiome Therapeutic, Reduces Abundance of Antimicrobial Resistance Genes in Patients with Recurrent Clostridioides difficile Infection (rCDI) after Standard-of-Care Antibiotics","display_name":"LB15. SER-109, an Investigational Microbiome Therapeutic, Reduces Abundance of Antimicrobial Resistance Genes in Patients with Recurrent Clostridioides difficile Infection (rCDI) after Standard-of-Care Antibiotics","publication_year":2021,"publication_date":"2021-11-01","ids":{"openalex":"https://openalex.org/W4200521908","doi":"https://doi.org/10.1093/ofid/ofab466.1651"},"language":"en","primary_location":{"id":"doi:10.1093/ofid/ofab466.1651","doi":"https://doi.org/10.1093/ofid/ofab466.1651","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofab466.1651","pdf_url":null,"source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4200521908"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1093/ofid/ofab466.1651","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5013637481","display_name":"Timothy J. Straub","orcid":"https://orcid.org/0000-0001-5009-0778","observed_orcids":["https://orcid.org/0000-0001-5009-0778"]},"institutions":[{"id":"https://openalex.org/I4210164905","display_name":"Seres Therapeutics (United States)","ror":"https://ror.org/05fn8qw23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164905"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Timothy J Straub","raw_affiliation_strings":["Seres Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seres Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164905"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113150263","display_name":"Liyang Diao","orcid":"https://orcid.org/0009-0001-4932-0916","observed_orcids":["https://orcid.org/0009-0001-4932-0916"]},"institutions":[{"id":"https://openalex.org/I4210164905","display_name":"Seres Therapeutics (United States)","ror":"https://ror.org/05fn8qw23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164905"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Liyang Diao","raw_affiliation_strings":["Seres Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seres Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164905"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008573434","display_name":"Christopher B. Ford","orcid":"https://orcid.org/0000-0002-4079-8673","observed_orcids":["https://orcid.org/0000-0002-4079-8673"]},"institutions":[{"id":"https://openalex.org/I4210164905","display_name":"Seres Therapeutics (United States)","ror":"https://ror.org/05fn8qw23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164905"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher Ford","raw_affiliation_strings":["Seres Therapeutics, Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seres Therapeutics, Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4210164905"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007426598","display_name":"Matthew D. Sims","orcid":"https://orcid.org/0000-0002-4427-6653","observed_orcids":["https://orcid.org/0000-0002-4427-6653"]},"institutions":[{"id":"https://openalex.org/I2799370151","display_name":"Beaumont Health","ror":"https://ror.org/05g2hd893","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I2799370151","https://openalex.org/I4392738273"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew Sims","raw_affiliation_strings":["Beaumont Health, Royal Oak, Michigan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beaumont Health, Royal Oak, Michigan","institution_ids":["https://openalex.org/I2799370151"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024258790","display_name":"Thomas Louie","orcid":"https://orcid.org/0000-0003-2131-0158","observed_orcids":["https://orcid.org/0000-0003-2131-0158"]},"institutions":[{"id":"https://openalex.org/I168635309","display_name":"University of Calgary","ror":"https://ror.org/03yjb2x39","country_code":"CA","type":"education","lineage":["https://openalex.org/I168635309"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Thomas J Louie","raw_affiliation_strings":["Cumming School of Medicine, University of Calgary, Calgary, Canada, Calgary, Alberta, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cumming School of Medicine, University of Calgary, Calgary, Canada, Calgary, Alberta, Canada","institution_ids":["https://openalex.org/I168635309"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056250710","display_name":"Charles S. Berenson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I63190737","display_name":"University at Buffalo, State University of New York","ror":"https://ror.org/01y64my43","country_code":"US","type":"education","lineage":["https://openalex.org/I63190737"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles Berenson","raw_affiliation_strings":["State University of New York at Buffalo, Buffalo, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"State University of New York at Buffalo, Buffalo, New York","institution_ids":["https://openalex.org/I63190737"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021420574","display_name":"Colleen S. Kraft","orcid":"https://orcid.org/0000-0003-1757-8477","observed_orcids":["https://orcid.org/0000-0003-1757-8477"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Colleen S Kraft","raw_affiliation_strings":["Emory University, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Emory University, Atlanta, GA","institution_ids":["https://openalex.org/I150468666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113126564","display_name":"Stuart H. Cohen","orcid":"https://orcid.org/0009-0001-0043-0508","observed_orcids":["https://orcid.org/0009-0001-0043-0508"]},"institutions":[{"id":"https://openalex.org/I84218800","display_name":"University of California, Davis","ror":"https://ror.org/05rrcem69","country_code":"US","type":"education","lineage":["https://openalex.org/I84218800"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stuart H Cohen","raw_affiliation_strings":["University of California, Davis, Sacramento, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California, Davis, Sacramento, California","institution_ids":["https://openalex.org/I84218800"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113126564","display_name":"Stuart H. Cohen","orcid":"https://orcid.org/0009-0001-0043-0508","observed_orcids":["https://orcid.org/0009-0001-0043-0508"]},"institutions":[{"id":"https://openalex.org/I84218800","display_name":"University of California, Davis","ror":"https://ror.org/05rrcem69","country_code":"US","type":"education","lineage":["https://openalex.org/I84218800"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stuart H Cohen","raw_affiliation_strings":["University of California, Davis, Sacramento, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California, Davis, Sacramento, California","institution_ids":["https://openalex.org/I84218800"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037322981","display_name":"Alla Paskovaty","orcid":"https://orcid.org/0000-0001-5654-8348","observed_orcids":["https://orcid.org/0000-0001-5654-8348"]},"institutions":[{"id":"https://openalex.org/I4210164905","display_name":"Seres Therapeutics (United States)","ror":"https://ror.org/05fn8qw23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164905"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alla Paskovaty","raw_affiliation_strings":["Seres Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seres Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164905"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038829006","display_name":"Mary\u2010Jane Lombardo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164905","display_name":"Seres Therapeutics (United States)","ror":"https://ror.org/05fn8qw23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164905"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary-Jane Lombardo","raw_affiliation_strings":["Seres Therapeutics, Inc, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seres Therapeutics, Inc, Cambridge, MA","institution_ids":["https://openalex.org/I4210164905"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025652958","display_name":"Barbara McGovern","orcid":"https://orcid.org/0000-0003-4451-2393","observed_orcids":["https://orcid.org/0000-0003-4451-2393"]},"institutions":[{"id":"https://openalex.org/I4210164905","display_name":"Seres Therapeutics (United States)","ror":"https://ror.org/05fn8qw23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164905"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Barbara McGovern","raw_affiliation_strings":["Seres Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seres Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164905"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009499028","display_name":"Lisa L. Von Moltke","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164905","display_name":"Seres Therapeutics (United States)","ror":"https://ror.org/05fn8qw23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164905"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa von Moltke","raw_affiliation_strings":["Seres Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seres Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164905"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5012021708","display_name":"Matt Henn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164905","display_name":"Seres Therapeutics (United States)","ror":"https://ror.org/05fn8qw23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164905"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matt Henn","raw_affiliation_strings":["Seres Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seres Therapeutics, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210164905"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3465,"currency":"USD","value_usd":3465},"apc_paid":{"value":3465,"currency":"USD","value_usd":3465},"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"8","issue":"Supplement_1","first_page":"S812","last_page":"S813"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11288","display_name":"Clostridium difficile and Clostridium perfringens research","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11288","display_name":"Clostridium difficile and Clostridium perfringens research","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10066","display_name":"Gut microbiota and health","score":0.007400000002235174,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10897","display_name":"Antibiotic Use and Resistance","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ser-109","display_name":"SER-109","score":0.9890000224113464},{"id":"https://openalex.org/keywords/recurrent-clostridioides-difficile-infection","display_name":"recurrent Clostridium difficile infection","score":0.9829999804496765},{"id":"https://openalex.org/keywords/antimicrobial-resistance-genes","display_name":"antimicrobial resistance genes","score":0.9729999899864197},{"id":"https://openalex.org/keywords/gut-microbiota","display_name":"gut microbiota","score":0.7250000238418579},{"id":"https://openalex.org/keywords/proteobacteria","display_name":"Proteobacteria","score":0.7239999771118164},{"id":"https://openalex.org/keywords/enterobacteriaceae","display_name":"Enterobacteriaceae","score":0.9980000257492065},{"id":"https://openalex.org/keywords/enterococcaceae","display_name":"Enterococcaceae","score":0.9919999837875366},{"id":"https://openalex.org/keywords/glycopeptide-resistance","display_name":"glycopeptide resistance","score":0.8920000195503235},{"id":"https://openalex.org/keywords/shotgun-metagenomics","display_name":"shotgun metagenomics","score":0.5429999828338623},{"id":"https://openalex.org/keywords/post-hoc-analysis","display_name":"post hoc analysis","score":0.5899999737739563},{"id":"https://openalex.org/keywords/antibiotic-exposure","display_name":"antibiotic exposure","score":0.35600000619888306},{"id":"https://openalex.org/keywords/microbiome-based-therapy","display_name":"microbiota-based therapy","score":0.5759999752044678},{"id":"https://openalex.org/keywords/clostridioides-difficile","display_name":"Clostridium difficile","score":0.6679999828338623}],"concepts":[{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.737933874130249},{"id":"https://openalex.org/C501593827","wikidata":"https://www.wikidata.org/wiki/Q12187","display_name":"Antibiotics","level":2,"score":0.6441066265106201},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6137749552726746},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6111229658126831},{"id":"https://openalex.org/C2910067853","wikidata":"https://www.wikidata.org/wiki/Q27438828","display_name":"Clostridioides","level":2,"score":0.5279594659805298},{"id":"https://openalex.org/C2777695942","wikidata":"https://www.wikidata.org/wiki/Q149075","display_name":"Firmicutes","level":4,"score":0.4992806911468506},{"id":"https://openalex.org/C4937899","wikidata":"https://www.wikidata.org/wiki/Q68541106","display_name":"Antimicrobial","level":2,"score":0.4875561594963074},{"id":"https://openalex.org/C94665300","wikidata":"https://www.wikidata.org/wiki/Q63391344","display_name":"Antibiotic resistance","level":3,"score":0.42673471570014954},{"id":"https://openalex.org/C143121216","wikidata":"https://www.wikidata.org/wiki/Q1330402","display_name":"Microbiome","level":2,"score":0.41772305965423584},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.41754305362701416},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.40051692724227905},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2731245160102844},{"id":"https://openalex.org/C523546767","wikidata":"https://www.wikidata.org/wiki/Q10876","display_name":"Bacteria","level":2,"score":0.16033494472503662},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.1330622136592865},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.08767896890640259},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.08721926808357239},{"id":"https://openalex.org/C42062724","wikidata":"https://www.wikidata.org/wiki/Q1209205","display_name":"16S ribosomal RNA","level":3,"score":0.06687664985656738},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1093/ofid/ofab466.1651","doi":"https://doi.org/10.1093/ofid/ofab466.1651","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofab466.1651","pdf_url":null,"source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1093/ofid/ofab466.1651","doi":"https://doi.org/10.1093/ofid/ofab466.1651","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofab466.1651","pdf_url":null,"source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2899701113","https://openalex.org/W4387564179","https://openalex.org/W2754909108","https://openalex.org/W3187617022","https://openalex.org/W4387169311","https://openalex.org/W4200584845","https://openalex.org/W4316084375","https://openalex.org/W2298483969","https://openalex.org/W4200265898","https://openalex.org/W4205375560"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"The":[2],"gastrointestinal":[3],"microbiota":[4,110],"is":[5,92,317],"the":[6,97,108,226,231,320],"first":[7],"line":[8],"of":[9,32,40,99,233,323,343,363,369],"defense":[10],"against":[11],"colonization":[12],"with":[13,22,116,196,217,225,230,245,319,339,372],"antimicrobial":[14,102],"resistant":[15],"(AR)":[16],"bacteria,":[17],"particularly":[18],"in":[19,48,67,107,147,168,201,263,281,298,306,325,366],"vulnerable":[20],"hosts":[21],"frequent":[23],"antibiotic":[24],"exposure.":[25],"In":[26],"a":[27,93,197,360],"double-blind":[28],"Phase":[29],"3":[30],"trial":[31],"rCDI":[33,117],"patients,":[34],"SER-109,":[35],"an":[36],"orally":[37],"formulated":[38],"consortia":[39],"purified":[41],"Firmicutes":[42],"spores,":[43],"was":[44,190,243,258,337],"superior":[45],"to":[46,112,125,165,178,310,350,528],"placebo":[47,70,128,205,267,285,328,351],"reducing":[49],"CDI":[50],"recurrence":[51,63],"at":[52,129,140,206,301,330,352],"week":[53,194,207,253,302,333,354],"8":[54],"post":[55,355],"clinical":[56],"resolution":[57],"on":[58,101],"standard-of-care":[59],"(SoC)":[60],"antibiotics.":[61],"Overall":[62],"rates":[64],"were":[65,122,145,155,163,176,214,276],"lower":[66],"SER-109":[68,100,126,202,264,282,307,326,336],"vs":[69,72],"(12.4%":[71],"39.8%,":[73],"respectively)":[74],"relative":[75,212,241,256,274,321],"risk,":[76],"0.32":[77],"[95%":[78],"CI,":[79],"0.18\u20130.58;":[80],"p<":[81,86],"0.001":[82,87,288],"for":[83,88,374],"RR<":[84,89],"1.0;":[85],"0.833].":[90],"This":[91],"post-hoc":[94],"analysis":[95],"examining":[96],"impact":[98],"resistance":[103],"genes":[104],"(ARGs)":[105],"abundance":[106,170,189,213,219,232,242,248,257,300,316,322],"intestinal":[109],"compared":[111,309,349],"placebo.":[113,311],"Methods":[114],"Subjects":[115],"received":[118],"SoC":[119],"antibiotics,":[120],"then":[121],"randomized":[123],"1:1":[124],"or":[127,454,463,471,479,496,510,521],"baseline.":[130],"Of":[131],"182":[132],"subjects,":[133],"140":[134],"who":[135],"had":[136],"paired":[137],"stool":[138],"samples":[139,222],"baseline":[141,262,280,305,331],"and":[142,152,181,272,289,327,332,345,427],"1-week":[143],"post-treatment":[144],"included":[146],"this":[148],"analysis.":[149],"ARG":[150,169,180,188,218,299,315],"abundances":[151,183,275,348],"taxonomic":[153],"profiles":[154],"generated":[156],"from":[157,171,261,279,304],"whole":[158],"metagenomic":[159],"shotgun":[160],"sequencing.":[161],"t-tests":[162],"used":[164,177],"compare":[166],"changes":[167],"baseline;":[172],"mixed":[173],"linear":[174],"models":[175],"associate":[179],"taxon":[182],"across":[184,220],"time":[185],"points.":[186],"Results":[187],"reduced":[191],"overall":[192],"by":[193],"1,":[195,254],"significantly":[198,259,340],"greater":[199,341],"decrease":[200],"subjects":[203,265,283,329],"vs.":[204,266,284],"1":[208,303,353],"(Fig.":[209,223],"1).":[210],"Proteobacteria":[211,255,324],"positively":[215],"correlated":[216],"all":[221],"2),":[224],"Enterobacteriaceae":[227,271],"family":[228],"associated":[229,244,318,338],"95":[234],"ARGs":[235,344],"(all":[236],"p":[237,290],"<":[238,250,269,287],"0.05).":[239],"Enterococcaceae":[240,273],"glycopeptide":[246],"AR":[247,346,370],"(p":[249,268,286],"0.001).":[251,270],"At":[252],"decreased":[260,278],"also":[277],"=":[291],"0.007,":[292],"respectively).":[293],"Figure":[294,312],"1.":[295,334],"Significant":[296],"reduction":[297,342],"treatment":[308],"2.":[313],"Total":[314],"Conclusion":[335],"bacteria":[347,371],"treatment.":[356],"These":[357],"findings":[358],"support":[359],"potential":[361],"role":[362],"microbiome":[364],"therapeutics":[365],"rapid":[367],"decolonization":[368],"implications":[373],"infection":[375],"prevention.":[376],"Disclosures":[377],"Timothy":[378],"J.":[379,449],"Straub,":[380],"MS,":[381],"Seres":[382,388,394,518,533,540,548,555],"Therapeutics":[383,389,395,439,445,467,486,534,541,549,556],"(Employee)":[384,390],"Liyang":[385],"Diao,":[386],"PhD,":[387,393,401,532,554],"Christopher":[391],"Ford,":[392],"(Employee,":[396,535,542,550,557],"Shareholder)":[397,536,543,551,558],"Matthew":[398],"Sims,":[399],"MD,":[400,451,503,517,526,539,547],"Astra":[402],"Zeneca":[403],"(Independent":[404,407,410,412,414,418,422,425,429,431,433,437,441,443,446],"Contractor)Diasorin":[405],"Molecular":[406],"Contractor)Epigenomics":[408],"Inc":[409,436,440],"Contractor)Finch":[411],"Contractor)Genentech":[413],"Contractor)Janssen":[415],"Pharmaceuticals":[416,435],"NV":[417],"Contractor)Kinevant":[419],"Sciences":[420],"gmBH":[421],"Contractor)Leonard-Meron":[423],"Biosciences":[424],"Contractor)Merck":[426],"Co":[428],"Contractor)OpGen":[430],"Contractor)Prenosis":[432],"Contractor)Regeneron":[434],"Contractor)Seres":[438],"Contractor)Shire":[442],"Contractor)Summit":[444],"Contractor)":[447],"Thomas":[448],"Louie,":[450],"Artugen":[452],"(Advisor":[453,462],"Review":[455,464,472,480,497,511],"Panel":[456,465,473,481,498,512],"member)Crestone":[457],"(Consultant,":[458,483,487],"Grant/Research":[459,484,488],"Support)Da":[460],"Volterra":[461],"member)Finch":[466],"(Grant/Research":[468,476,491,493],"Support,":[469,477,494],"Advisor":[470,478,495,509],"member)MGB":[474],"Biopharma":[475],"member)Rebiotix":[482],"Support)Seres":[485],"Support)Summit":[489],"PLC":[490],"Support)Vedanta":[492],"member)":[499],"Colleen":[500],"S.":[501],"Kraft,":[502],"MSc,":[504],"Rebiotix":[505],"(Individual(s)":[506],"Involved:":[507],"Self):":[508],"member":[513],"Stuart":[514,523],"H.":[515,524],"Cohen,":[516,525],"(Research":[519],"Grant":[520],"Support)":[522],"Nothing":[527],"disclose":[529],"Mary-Jane":[530],"Lombardo,":[531],"Barbara":[537],"McGovern,":[538],"Lisa":[544],"von":[545],"Moltke,":[546],"Matt":[552],"Henn,":[553]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-13T13:42:25.865203","created_date":"2021-12-31T00:00:00"}